A judge in the US has denied an attempt by Novartis to stop MSN Pharmaceuticals from launching a generic version of heart failure blockbuster Entresto.
At the start of this year, Bayer said there were two important trial readouts for the company to deliver near-term growth this year as it rebuilds its pipeline – and both have now delivered
Shares in NewAmsterdam Pharma were sliding today after it reported a phase 3 trial of obicetrapib that met its primary objective but didn't meet the expectations of some analysts and invest
Off-the-shelf consumer wearables have shown a benefit when used to monitor the response to treatment in patients with atrial fibrillation (AF) and heart failure (HF).
AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower
New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl